# A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

> **NCT03533244** · PHASE2 · COMPLETED · sponsor: **Allgenesis Biotherapeutics Inc.** · enrollment: 64 (actual)

## Conditions studied

- Pterygium

## Interventions

- **DRUG:** 0.1% AG-86893 Eye Drops
- **DRUG:** 0.3% AG-86893 Eye Drops
- **DRUG:** Vehicle Eye Drops

## Key facts

- **NCT ID:** NCT03533244
- **Lead sponsor:** Allgenesis Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2019-09-05
- **Final completion:** 2019-10-25
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533244, "A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03533244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*